FOLR1 Rabbit Polyclonal Antibody (ER1901-95)

UNIPROT #

P15328

PROTEIN NAME

FOLR1

SYNONYMS

adult antibody;Adult folate binding protein antibody;Adult folate-binding protein antibody;FBP antibody;Folate Binding Protein antibody;Folate Receptor 1 Adult antibody;Folate receptor 1 antibody;Folate Receptor 1 Precursor antibody;Folate receptor adult antibody;Folate receptor alpha antibody;Folate receptor antibody;FOLR antibody;FOLR1 antibody;FOLR1_HUMAN antibody;FR alpha antibody;FR-alpha antibody;FRalpha antibody;KB cells FBP antibody;MOV18 antibody;Ovarian cancer associated antigen antibody;Ovarian tumor associated antigen antibody;Ovarian tumor associated antigen MOv18 antibody;Ovarian tumor-associated antigen MOv18 antibody

SEQUENCE SIMILARITIES

Belongs to the folate receptor family.

TISSUE SPECIFICITY

Primarily expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum. Detected in placenta and thymus epithelium.

POST-TRANSLATIONAL MODIFICATION

The secreted form is derived from the membrane-bound form either by cleavage of the GPI anchor, or/and by proteolysis catalyzed by a metalloprotease.

SUBCELLULAR LOCATION

Cell membrane, Cytoplasmic vesicle, Endosome, Membrane, Secreted.

FUNCTION

Folate receptor 1 (Folate receptor alpha, FOLR1) is a protein that in humans is encoded by the FOLR1 gene. The protein encoded by this gene is a member of the folate receptor (FOLR) family. Members of this family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. This gene is composed of 7 exons; exons 1 through 4 encode the 5' UTR and exons 4 through 7 encode the open reading frame. Due to the presence of 2 promoters, multiple transcription start sites, and alternative splicing of exons, several transcript variants are derived from this gene. These variants differ in the lengths of 5' and 3' UTR, but they encode an identical amino acid sequence. FRA can be overexpressed by a number of epithelial-derived tumors including ovarian, breast, renal, lung, colorectal, and brain. Hence antibodies to it are used in targeted therapies and diagnostic tests, e.g. farletuzumab in phase III trial for ovarian cancer. Autoantibodies to the FRA have been linked to neurodevelopmental diseases, particularly cerebral folate deficiency schizophrenia and autism spectrum disorder. Recent studies have shown that these neurodevelopmental disorders can be treated with folinic acid.